Sign in

    Brice Thomas

    Research Analyst at North Growth Asset Management

    Brice Thomas is a Research Analyst at North Growth Asset Management, focusing on investment analysis and coverage within the biotechnology sector. He has specifically covered companies such as Sonnet BioTherapeutics, actively participating in their earnings calls and providing direct analytical input. Thomas began his career at North Growth Asset Management, where he has contributed to the firm's research activities, though comprehensive public data on his prior experience and quantitative performance metrics remains limited. Professional details such as FINRA registration and securities licenses are not publicly available, and notable achievements or industry rankings have not yet been documented.

    Brice Thomas's questions to Sonnet BioTherapeutics Holdings (SONN) leadership

    Brice Thomas's questions to Sonnet BioTherapeutics Holdings (SONN) leadership • Q3 2016

    Question

    Brice Thomas asked for an explanation of the strong store economics of the Little Big Burger concept and sought confirmation that the company's '2020 plan' for growth is entirely organic.

    Answer

    CEO Michael Pruitt and COO Mark Roberson attributed Little Big Burger's strong economics to its 'elegantly simple model,' featuring a small menu, a small physical footprint (1,200-1,600 sq ft), and low labor needs, which significantly reduces operating and opening costs. They also highlighted its cult-like following that minimizes marketing expenses. Pruitt confirmed the 2020 plan to double store count is purely organic, funded through franchising, a joint venture partnership, and EB5 financing.

    Ask Fintool Equity Research AI